Table 3.
Risk of disability worsening after completion of therapy (HR) and 95% confidence intervals for the Cox model
| Model 1 | Model 2 | Model 3 | ||||||
|---|---|---|---|---|---|---|---|---|
| Bivariate | Socio-demographic variables | Clinical variables | Reaction variables | |||||
| Variables | HR | 95% IC | HR | 95% IC | HR | 95% IC | HR | 95% IC |
| Socio-demographic variables | ||||||||
| Gender | ||||||||
| Female | 1 | 1 | 1 | 1 | ||||
| Male | 1.29 | 0.81–2.03 | 1.28 | 0.81–2.02 | 1.08 | 0.67–1.72 | 1.11 | 0.69–1.76 |
| Age (continuous) | 1.01 | 0.99–1.02 | 1.01 | 0.99–1.02 | 1.00 | 0.99–1.01 | 1.00 | 0.99–1.02 |
| Education (school years) | ||||||||
| ≥11 | 1 | |||||||
| 8–10 | 1.40 | 0.66–2.96 | ||||||
| <8 | 1.32 | 0.68–2.56 | ||||||
| Clinical variables | ||||||||
| Clinical forms | ||||||||
| BB | 1 | |||||||
| BL | 1.37 | 0.81–2.30 | ||||||
| LL | 1.06 | 0.63–1.79 | ||||||
| Skin lesions | ||||||||
| Up to 15 | 1 | 1 | 1 | |||||
| More than 15 | 2.01 | 1.10–3.68 | 2.06 | 1.12–3.78 | 1.97 | 1.07–3.63 | ||
| Edema | ||||||||
| No | 1 | |||||||
| Yes | 1.13 | 0.77–1.67 | ||||||
| Cyanosis | ||||||||
| No | 1 | |||||||
| Yes | 1.72 | 1.14–2.59 | ||||||
| Initial bacillary index (continuous) | 1.02 | 0.89–1.17 | ||||||
| Initial diasability grade | 1 | |||||||
| 0 | 1 | 1.82 | 1.16–2.86 | 1.61 | 1.02–2.56 | |||
| 1 | 2.03 | 1.32–3.14 | 2.77 | 1.60–4.77 | 2.37 | 1.35–4.16 | ||
| 2 | 2.80 | 1.65–4.74 | ||||||
| Reaction variables | ||||||||
| Reaction episodes | ||||||||
| No | 1 | |||||||
| Yes | 1.96 | 1.05–3.66 | ||||||
| Reversal reaction | ||||||||
| No | 1 | |||||||
| Yes | 1.55 | 1.04–2.31 | ||||||
| ENL | ||||||||
| No | 1 | |||||||
| Yes | 0.99 | 0.67–1.46 | ||||||
| Neuritis | ||||||||
| No | 1 | 1 | ||||||
| Yes | 1.90 | 1.28–2.84 | 1 | 1.65 | 1.08–2.52 | |||
| Model results | ||||||||
| LR (loglik) | −545.74 | −535.54 | −532.71 | |||||
| P-value | 0.061 | 0.000 | 0.017 | |||||
LR, Likelihood ratio function test.